Focusing on the Potential of Midsized Pharma Service Organizations

March 2, 2022 PAO-03-22-R250-03

At this stop on the Road to 50 States trip, Brian Scanlan, Operating Partner at Edgewater Capital, talks to Nigel about the importance of midsize life sciences companies and why it's important to strengthen the supply base in the United States and Europe.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.

Edgewater Capital Partners

Edgewater Capital Partners is a private equity firm unlike any other. Our difference is summarized by our three foundational pillars: Deep Sector Expertise, Midwestern Values, and a Growth Enabling Philosophy. Every company we review, every investment we make, and every action we take is guided by these fundamental principles.

Unlike other firms, the Edgewater team is solely focused on four industry sectors: Specialty Industrials, Life Science, Advanced Materials, and Specialty Chemicals. We’ve invested in businesses in these sectors for decades, and as a result, we have developed and built dedicated expertise within thesis-specific practice areas by our Operating Partners. Edgewater’s unique focus and deep expertise results in accelerated diligence and a greater certainty to close; two things sellers consistently say is a signature of Edgewater

Q: